Log in

EPA:SANSanofi Stock Price, Forecast & News

€88.92
-0.26 (-0.29 %)
(As of 07/10/2020 04:00 PM ET)
Add
Compare
Today's Range
€88.74
Now: €88.92
€89.70
50-Day Range
€86.18
MA: €89.98
€94.12
52-Week Range
€63.09
Now: €88.92
€92.97
Volume1.66 million shs
Average Volume3.05 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis. The company also provides Jevtana, a taxane derivative for prostate cancer; Taxotere, a taxoid for cancers; Eloxatin, an agent for colorectal cancer; Thymoglobulin, an immunosuppressive and immunomodulating agent; Mozobil, a hematopoietic stem cell mobilizer; and Zaltrap, a protein for metastatic colorectal cancer. In addition, it offers Dupixent for atopic dermatitis; Kevzara for rheumatoid arthritis; Lantus, Toujeo, Apidra, and Insuman insulins; Amaryl, an oral sulfonylurea; Lyxumia/Adlyxin, a GLP-1 receptor agonist; Soliqua 100/33/Suliqua, an insulin glargine and lixisenatide combination to treat diabetes; Admelog/Insulin lispro insulin; Praluent, a cholesterol-lowering drug; and Multaq, an anti-arrhythmic drug for atrial fibrillation. Further, the company provides Plavix, an anti-platelet agent for atherothrombotic conditions; Lovenox, a heparin for the prophylaxis and venous thromboembolism and acute coronary syndrome; Aprovel and CoAprovel anti-hypertensives; Renagel and Renvela oral phosphate binders for patients undergoing dialysis; Synvisc and Synvisc-One viscosupplements for osteoarthritis; Stilnox for insomnia; and Allegra for seasonal allergic rhinitis and uncomplicated hives. Additionally, it offers consumer health care products and generic medicines; and pediatric, influenza, adult and adolescent booster, meningitis, and travel and endemic vaccines. Sanofi has strategic alliance with Sensile Medical Ltd.; collaboration with Evotec AG; and partnership with REVOLUTION Medicines, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Read More
Sanofi logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.16 out of 5 stars


Industry, Sector and Symbol

Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+33-1-53774000

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableOptionable

Receive SAN News and Ratings via Email

Sign-up to receive the latest news and ratings for SAN and its competitors with MarketBeat's FREE daily newsletter.

Sanofi (EPA:SAN) Frequently Asked Questions

How has Sanofi's stock been impacted by COVID-19 (Coronavirus)?

Sanofi's stock was trading at €79.63 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, SAN shares have increased by 11.7% and is now trading at €88.92. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Sanofi?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sanofi in the last year. There are currently 2 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Sanofi.

What price target have analysts set for SAN?

13 equities research analysts have issued 1-year target prices for Sanofi's stock. Their forecasts range from €80.00 to €110.00. On average, they anticipate Sanofi's share price to reach €100.69 in the next year. This suggests a possible upside of 13.2% from the stock's current price. View analysts' price targets for Sanofi.

Has Sanofi been receiving favorable news coverage?

News headlines about SAN stock have trended somewhat negative this week, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Sanofi earned a media sentiment score of -1.2 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news about Sanofi.

Who are some of Sanofi's key competitors?

What other stocks do shareholders of Sanofi own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sanofi investors own include Skechers USA (SKX), Sanofi (SNY), Encana (ECA), Tronox (TROX), Bank of America (BAC), NVIDIA (NVDA), salesforce.com (CRM), ServiceNow (NOW), Baidu (BIDU) and Intel (INTC).

Who are Sanofi's key executives?

Sanofi's management team includes the following people:
  • Mr. Olivier Brandicourt, CEO & Director (Age 63)
  • Mr. Jean-Baptiste Chasseloup de Chatillon, Exec. VP & CFO (Age 54)
  • Mr. Laurent Gilhodes, Principal Accounting Officer and VP of Corp. Accounting
  • Mr. Bruno Ménard, Chief Information officer
  • Mr. George Grofik, Head of Investor Relations

What is Sanofi's stock symbol?

Sanofi trades on the EPA under the ticker symbol "SAN."

What is Sanofi's stock price today?

One share of SAN stock can currently be purchased for approximately €88.92.

What is Sanofi's official website?

The official website for Sanofi is en.sanofi.com.

How can I contact Sanofi?

Sanofi's mailing address is 54 rue la Boetie, PARIS, 75008, France. The company can be reached via phone at +33-1-53774000.

This page was last updated on 7/11/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.